Price T Rowe Associates Inc 2seventy Bio, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 28,929 shares of TSVT stock, worth $138,859. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,929
Previous 28,929
-0.0%
Holding current value
$138,859
Previous $155,000
27.74%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding TSVT
# of Institutions
122Shares Held
48.2MCall Options Held
211KPut Options Held
9.7K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$28.6 Million1.78% of portfolio
-
Goldman Sachs Group Inc New York, NY4.14MShares$19.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$17.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$17.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.27MShares$15.7 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $182M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...